Abstract:Oxygen is ubiquitous on the Earth’s surface and essential for the survival of almost all eukaryotes. Nearly all living organisms require molecular oxygen for the metabolism of the macro-molecules to obtain energy for growth, development and reproduction. It is the subject of immense physiological, biochemical and clinical literature. In response to inadequate oxygen availability, eukaryotic body or cells undergo adaptive changes in gene expression program that either enhance oxygen delivery or promote survival in a low oxygen environment. The discovery of the mechanism by which cells sense and adapt to oxygen availability, which is awarded the 2019 Nobel Prize in Physiology or Medicine, lays the foundation for understanding how oxygen affects multiple physiological and pathological process. Hypoxia-inducible factor 1 (HIF-1) lies at the center of the hypoxia signal transduction pathway. HIF-1 was identified in a search for molecules that enhance erythropoietin (EPO) expression in anemia or hypoxia. HIF-1 is a heterodimer composed of α and β subunits, each containing basic helix-loop-helix-PAS (bHLH-PAS) domains. HIF-1β is constitutively expressed, while HIF-1α expression depends on oxygen availability and only a limited amount of protein is stabilized in the cytoplasm. Under hypoxic conditions, expressed cytosolic HIF-1α is stabilized and translocated into the nucleus to form heterodimers with HIF-1β, then binds to hypoxia response elements (HREs) to initiate transcription of target genes. More than 1000 genes have been identified to be directly transcriptionally activated by HIF-1. The proteins encoded by HIF-1 target genes are usually divided into 2 categories: one is those proteins that increase oxygen delivery like EPO, vascular endothelial growth factor (VEGF) et al, and the other is those proteins that decrease oxygen consumption like lactate dehydrogenase A (LDHA), pyruvate dehydrogenase kinase 1 (PDK1) and so on. Under normoxic conditions, prolyl hydroxylase 2 (PHD2), which serves as the sensor of cellular oxygen levels, hydroxylates the conserved proline residues in the α subunit of HIF-1. Hydroxylated HIF-1α is recognized and bound by the ubiquitin ligase von Hippel-Lindau (VHL)/Elongin B/Elongin C/Cullin-2 complex, leading to its rapid degradation by the proteasome. HIF-1α transcription activity is negatively regulated by factor inhibiting HIF-1 (FIH-1) via FIH-1-dependent asparaginyl hydroxylation using oxygen and a-ketoglutarate as substrates, which blocks the association of the coactivators CBP (CREB-binding protein) and p300. Abnormal hypoxia signal transduction contributes to the pathogenesis of many kinds of diseases like hypertension, ocular neovascularization, cancer, erythrocytosis and so on. Currently, extensive efforts are ongoing to develop drugs for clinical treatment of hypoxia-related diseases.

[The development of innovative therapeutic drugs targeting hypoxia responses]

Discoveries of how cells sense oxygen win the 2019 Nobel Prize in Physiology or medicine

The Discovery of How Cells Sense and Adapt to Oxygen Availability

Hypoxia-inducible Factor-1: a Key Protein for Cells Adapting to Changes in Oxygen Supply

Oxygen sensing and adaptability won the 2019 Nobel Prize in Physiology or medicine

[Future perspectives of treatment for anemia in chronic kidney disease (CKD) using hypoxia-inducible factor prolyl hydroxylase inhibitors]

Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications

Targeting hypoxia-inducible factors: therapeutic opportunities and challenges

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Recent Advances in the Study of Bioreductive Drugs Targeted Tumor Hypoxia

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

Disturbance of Hypoxia Response and Its Implications in Kidney Diseases.

Hypoxia signaling in human diseases and therapeutic targets

Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016-2020)

Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy

Novel Therapeutic Targets for Hypoxia-Related Cardiovascular Diseases: The Role of HIF-1

Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A “structure-activity relationship” perspective

A patent review on hypoxia-inducible factor (HIF) modulators (2021–2023)

Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases

[New Advances in Oxygen Sensing and Adaptive Mechanism].

How to overcome (and exploit) tumor hypoxia for targeted gene therapy